Matches in SemOpenAlex for { <https://semopenalex.org/work/W3115344203> ?p ?o ?g. }
- W3115344203 endingPage "1120" @default.
- W3115344203 startingPage "1102" @default.
- W3115344203 abstract "Hepatocellular carcinoma (HCC) is a major cause of concern as it has substantial morbidity associated with it. Previous reports have ascertained the antiproliferative activity of imatinib mesylate (IMS) against diverse types of carcinomas, but limited bioavailability has also been reported. The present study envisaged optimized IMS-loaded lactoferrin (LF)-modified PEGylated liquid crystalline nanoparticles (IMS-LF-LCNPs) for effective therapy of IMS to HCC via asialoglycoprotein receptor (ASGPR) targeting. Results displayed that IMS-LF-LCNPs presented an optimum particle size of 120.40 ± 2.75 nm, a zeta potential of +12.5 ± 0.23 mV, and 73.94 ± 2.69% release. High-resolution transmission electron microscopy and atomic force microscopy were used to confirm the surface architecture of IMS-LF-LCNPs. The results of cytotoxicity and 4,6-diamidino-2-phenylindole revealed that IMS-LF-LCNPs had the highest growth inhibition and significant apoptotic effects. Pharmacokinetics and biodistribution studies showed that IMS-LF-LCNPs have superior pharmacokinetic performance and targeted delivery compared to IMS-LCNPs and plain IMS, which was attributed to the targeting action of LF that targets the ASGPR in hepatic cells. Next, our in vivo experiment established that the HCC environment existed due to suppression of BAX, cyt c, BAD, e-NOS, and caspase (3 and 9) genes, which thus owed upstream expression of Bcl-xl, iNOS, and Bcl-2 genes. The excellent therapeutic potential of IMS-LF-LCNPs began the significant stimulation of caspase-mediated apoptotic signals accountable for its anti-HCC prospect. 1H nuclear magnetic resonance (serum) metabolomics revealed that IMS-LF-LCNPs are capable of regulating the disturbed levels of metabolites linked to HCC triggered through N-nitrosodiethylamine. Therefore, IMS-LF-LCNPs are a potentially effective formulation against HCC." @default.
- W3115344203 created "2021-01-05" @default.
- W3115344203 creator A5012146396 @default.
- W3115344203 creator A5012613217 @default.
- W3115344203 creator A5043195275 @default.
- W3115344203 creator A5044140072 @default.
- W3115344203 creator A5048364915 @default.
- W3115344203 creator A5052491503 @default.
- W3115344203 creator A5057305533 @default.
- W3115344203 creator A5058701155 @default.
- W3115344203 creator A5066373911 @default.
- W3115344203 creator A5075559034 @default.
- W3115344203 date "2020-12-23" @default.
- W3115344203 modified "2023-09-22" @default.
- W3115344203 title "Fabrication of Imatinib Mesylate-Loaded Lactoferrin-Modified PEGylated Liquid Crystalline Nanoparticles for Mitochondrial-Dependent Apoptosis in Hepatocellular Carcinoma" @default.
- W3115344203 cites W1219934235 @default.
- W3115344203 cites W1263395533 @default.
- W3115344203 cites W1517930470 @default.
- W3115344203 cites W1713371841 @default.
- W3115344203 cites W184834241 @default.
- W3115344203 cites W1947473797 @default.
- W3115344203 cites W1966810323 @default.
- W3115344203 cites W1974055353 @default.
- W3115344203 cites W1976327004 @default.
- W3115344203 cites W1981556226 @default.
- W3115344203 cites W1982359144 @default.
- W3115344203 cites W1991333913 @default.
- W3115344203 cites W1995676656 @default.
- W3115344203 cites W1996179790 @default.
- W3115344203 cites W2025701648 @default.
- W3115344203 cites W2028339480 @default.
- W3115344203 cites W2041493424 @default.
- W3115344203 cites W2057428268 @default.
- W3115344203 cites W2061126659 @default.
- W3115344203 cites W2067091449 @default.
- W3115344203 cites W2070881021 @default.
- W3115344203 cites W2083032445 @default.
- W3115344203 cites W2085260077 @default.
- W3115344203 cites W2092966054 @default.
- W3115344203 cites W2134351178 @default.
- W3115344203 cites W2136635797 @default.
- W3115344203 cites W2138292212 @default.
- W3115344203 cites W2207806713 @default.
- W3115344203 cites W2291703838 @default.
- W3115344203 cites W2325424191 @default.
- W3115344203 cites W2330326295 @default.
- W3115344203 cites W2345128149 @default.
- W3115344203 cites W2462273684 @default.
- W3115344203 cites W2531766156 @default.
- W3115344203 cites W2591061287 @default.
- W3115344203 cites W2601821901 @default.
- W3115344203 cites W2603141830 @default.
- W3115344203 cites W2618539217 @default.
- W3115344203 cites W2618853782 @default.
- W3115344203 cites W2727748252 @default.
- W3115344203 cites W2737827748 @default.
- W3115344203 cites W2789291989 @default.
- W3115344203 cites W2795953388 @default.
- W3115344203 cites W2805621578 @default.
- W3115344203 cites W2888693875 @default.
- W3115344203 cites W2896681451 @default.
- W3115344203 cites W2897047680 @default.
- W3115344203 cites W2909763574 @default.
- W3115344203 cites W2914481309 @default.
- W3115344203 cites W2916356288 @default.
- W3115344203 cites W2940490146 @default.
- W3115344203 cites W2944871112 @default.
- W3115344203 cites W2955931202 @default.
- W3115344203 cites W2961232713 @default.
- W3115344203 cites W2966861985 @default.
- W3115344203 cites W2979665159 @default.
- W3115344203 cites W2981388255 @default.
- W3115344203 cites W2998507811 @default.
- W3115344203 cites W2998919112 @default.
- W3115344203 cites W3002497505 @default.
- W3115344203 cites W3009429985 @default.
- W3115344203 cites W3045258940 @default.
- W3115344203 cites W3084402305 @default.
- W3115344203 cites W315781246 @default.
- W3115344203 cites W4230955066 @default.
- W3115344203 cites W4234909651 @default.
- W3115344203 doi "https://doi.org/10.1021/acs.molpharmaceut.0c01024" @default.
- W3115344203 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33356314" @default.
- W3115344203 hasPublicationYear "2020" @default.
- W3115344203 type Work @default.
- W3115344203 sameAs 3115344203 @default.
- W3115344203 citedByCount "15" @default.
- W3115344203 countsByYear W31153442032021 @default.
- W3115344203 countsByYear W31153442032022 @default.
- W3115344203 countsByYear W31153442032023 @default.
- W3115344203 crossrefType "journal-article" @default.
- W3115344203 hasAuthorship W3115344203A5012146396 @default.
- W3115344203 hasAuthorship W3115344203A5012613217 @default.
- W3115344203 hasAuthorship W3115344203A5043195275 @default.
- W3115344203 hasAuthorship W3115344203A5044140072 @default.
- W3115344203 hasAuthorship W3115344203A5048364915 @default.
- W3115344203 hasAuthorship W3115344203A5052491503 @default.
- W3115344203 hasAuthorship W3115344203A5057305533 @default.